Home
overview

Following the success of our first event in 2003, SMi are proud to present their 2nd strategic forum on Depression and Anxiety to be held in London this June. We have invited key industry experts to explore the current and future opportunities within psychopharmacotherapy, namely the growing challenges of diagnosing and treating the spectrum of distinct disorders.

Register now to secure your place and join us in central London on 28th & 29th June 2006, to get the opportunity to meet some of the leading lights of the global psychopharmaceutical community as they share their insights and expertise.

Some of our confirmed speakers:

  • Dr Phil Skolnick Senior Vice President, Research & Chief Scientific Officer, DOV Pharmaceuticals
  • Dr Amir Kalali, Vice President, Medical & Scientific Services, Global Scientific Head, CNS Therapeutics, Quintiles
  • Dr Phil Gerrard, Director, Behavioural Neuroscience, Psychiatry Centre of Excellence Drug Discovery, GlaxoSmithKline,
  • Dr Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring, Johnson & Johnson Pharmaceutical Research & Development
  • Dr Hugh Marston, Head, Neurobiology Section, Department of Pharmacology, Organon Laboratories
  • Professor Phillip Cowen, Head, Psychopharmacology Research Unit, Oxford University
  • Kim Domela Kjøller, Director, Strategic Marketing Division, Lundbeck
  • Dr Eduardo Dunayevich, Medical Advisor, Lilly Research Laboratories
  • SMi’s 2nd conference on Depression and Anxiety aims to uncover the latest clinical and commercial factors affecting the key industry players in the psychopharmaceuticals market. The conference will feature presentations from senior industry practitioners, leading academic researchers, and cutting edge bio-technical laboratories from around the world. These scientists have dedicated their careers to unravelling the mysteries of the novel factors found within psychiatric disease in order to to create the most innovative and effective treatments. Efforts to better treat schizophrenia, depression, anxiety, bipolar disease, psychosis, and related indications will be described. Strategies for bringing these new therapies to patients will also be addressed, with a focus on translational clinical research and development specially designed to combat these debilatating mood disorders.

    This two day intensive forum will help you learn more about:

    THE PSYCHOPHARMACOTHERAPY MARKET: Review the latest offerings to emerge from the psychopharmaceutical drug development pipeline and what opportunities and obstacles lie ahead in this dynamic but increasingly hostile market

    MOOD DISORDERS: Consider the different indications found within the distinct disorder spectrum and the new therapeutic approaches currently being devised to combat unmet medical needs

    PSYCHOGENOMICS: Discover how genetics could provide the key to producing a truly individualised therapy system, and how the latest discoveries could help salvage previously doomed drug candidates

    TRANSLATIONAL ISSUES: Evaluate the latest technologies to be used in identifying relevant biomarkers and measurement scales overcoming the traditional obstacles inherent within the CNS clinical trial process

    COMBINATION THERAPIES: Appraise the recent advances in novel neurotherapeutic solutions and join the debate raging between pharmacotherapy and psychotherapy – what are the resulting long-term implications?

    STRATEGIC SOLUTIONS: Gain a unique insight into and a greater understanding of how big pharma approach the challenges faced by the psychopharmacological community

    INFORMAL INTERACTION: Take the opportunity to mingle with key thinkers, test their knowledge during an interactive panel discussion and benefit from their shared experien

    Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Philip Gerrard

    Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline - (Moderator)

    9:10 DETAILED R&D THEMES BY THERAPY AREAS AND DRUG MECHANISMS

    Philip Gerrard

    Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline - (Moderator)

  • Modulation of central monoamine systems
  • Dysfunction of the hypothalamic-pituitary-adrenal ( HPA) axis
  • Neuronal plasticity
  • Inflammatory mediators
  • Future perspectives
  • 9:50 INNOVATIVE APPROACHES TO DECIPHERING THE CAUSES OF DEPRESSION AND ANXIETY

    Pim Drinkenburg

    Pim Drinkenburg, Head, CNS Center of Expertise - Biomonitoring , Johnson & Johnson Pharmaceutical Research & Development

  • Decoding depression - from classical monaminergics to novel antidepressant mechanisms
  • Linking behavioural biology and clinical psychopharmacology: Can CNS biomarkers help out?
  • Developing relevant in vivo assays and technologies to aid translational studies
  • Collaboration - is outsourcing the key to success
  • 10:30 Morning Coffee

    11:00 MODULATION OF NEURONAL NICOTINIC RECEPTORS (NNRs) IN DEPRESSION AND ANXIETY

    Geoffrey Dunbar

    Geoffrey Dunbar, Senior Vice President, Clinical Development & RA, Targacept Inc

  • Smoking and depression are linked clinically. Can a new radical treatment effect both disorders?
  • All antidepressants are antagonists at NNRs
  • Introducing mecamylamine as an effective add-on treatment to patients who fail to respond to fluoxetine
  • Presenting TC-2216 a selective NNR antagonist with preclinical features of an antidepressant/anti-anxiety agent
  • Potential for TC-2216 as an anti-smoking therapy
  • 11:40 THE RELEVANCE OF CLINICAL TRIALS IN DEPRESSION AND ANXIETY

    Alan Lenox-Smith

    Alan Lenox-Smith, Senior Medical Advisor, Wyeth

  • Controlled vs naturalistic studies
  • Efficacy vs effectiveness
  • Endpoints - which should be primary?
  • Interpreting meta-analysis
  • Beyond tolerability
  • 12:20 Networking Lunch

    13:50 GABA RECEPTORS: DRUG TARGETS IN AN AGE OF ANXIETY?

    Phil Skolnick

    Phil Skolnick, Senior VP, Research & CSO, DOV Pharmaceutical, Inc.

  • The role of GABAergic pathways in anxiety disorders
  • Hunting for anxioselective agents: what have we learnt from transgenic mice?
  • Do currently prescribed anxiolytics short change patients?
  • Studies with Ocinaplon, a novel GABAA receptor modulator, in GAD
  • 14:30 WHY GOOD DRUGS GO BAD?

  • Criteria for moving to the clinic
  • Surrogate markers and proof of concept
  • Key elements of efficacy study design
  • Dose finding
  • Target investigational populations
  • David  Michelson

    David Michelson, Executive Director, Neuroscience Medical Research, Lilly Research Laboratories

    Eduardo Dunayevich

    Eduardo Dunayevich, Medical Advisor, Eli Lilly & Co

    15:10 Afternoon Tea

    15:40 CASE STUDY: ABILIFY – FROM BENCH TO BEDSIDE

  • Benefits of partial receptor agonism
  • Advantages of multiple mechanisms
  • Widespread applications of atypical antipsychotics
  • Looking ahead: Harnessing genomics to create new drug candidates
  • C. Anthony Altar

    C. Anthony Altar, President & Chief Scientific Officer, Pychiatric Genomics Inc

    C. Anthony Altar

    C. Anthony Altar, President & Chief Scientific Officer, Pychiatric Genomics Inc

    16:20 WHAT LIES AHEAD FOR ANTIDEPRESSANT THERAPY?

    Pim Drinkenburg

    Pim Drinkenburg, Head, Biomonitoring Research RED, Europe & Research Fellow, Johnson & Johnson

    Geoffrey Dunbar

    Geoffrey Dunbar, Senior Vice President, Clinical Development & RA, Targacept Inc

    Anthony Altar

    Anthony Altar, Presdent & Chief Scientific Officer, Pychiatric Genomics Inc

    Philip Gerrard

    Philip Gerrard, Director, Behavioural Neuroscience, GlaxoSmithKline - (Moderator)

    Phil Skolnick

    Phil Skolnick, Senior VP, Research & CSO, DOV Pharmaceutical, Inc.

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Amir Kalali

    Amir Kalali, Vice President, Medical & Scientific Services & Global Scientific Head CNS, Quintiles

    9:10 CRISIS AND OPPORTUNITY: CHALLENGES FACING CNS DRUG DEVELOPMENT IN 2006

  • A review of issues facing all CNS drug developers currently
  • Discussion of the dangers to the viability of CNS drug development
  • Ideas on how we might overcome these challenges
  • Amir Kalali

    Amir Kalali, Vice President, Medical & Scientific Services & Global Scientific Head CNS, Quintiles

    Amir Kalali

    Amir Kalali, Vice President, Medical & Scientific Services & Global Scientific Head CNS, Quintiles

    9:50 CAN PSYCHOPHARMACOGENOMICS ELIMINATE THE NEED FOR TRIAL AND ERROR TREATMENT

    Maria  Athanasiou

    Maria Athanasiou, Senior Project Manager, Genaissance Pharmaceuticals Inc.

  • The quest for drug therapy in depression based on genetics.
  • Identifying new genetic markers used to predict patient response
  • Demonstrating pipeline benefits– rescuing Vilazodone.
  • 10:30 Morning Coffee

    11:00 SHEDDING LIGHT ON THE PSYCHOPHARMACEUTICAL CONUNDRUM

    Phillip Cowen

    Phillip Cowen, Head, Psychopharmacology Research Unit , Department of Psychiatry, University of Oxford

  • The history and limitations of classical psychopharmacological approaches to drug action
  • Effects of psychotropic drugs on measures of emotional processing
  • Surrogate markers of drug action on emotional circuitry
  • Future prospects for understanding pathophysiology and facilitating drug development
  • 11:40 ADDRESSING THE PHENOMENA OF HIGH PLACEBO RESPONSE RATES

    Joshua Lipsitz

    Joshua Lipsitz, Assistant Professor Clinical Psychology, Department of Psychiatry, Columbia University , MedAvante, Inc

  • Baseline inflation
  • Applied vs. passive rating skills
  • The relationship of rater skills to assay sensitivity
  • A strategy for enhancing and monitoring clinical rater performance in multi-site trials
  • Using technology to improve results
  • 12:20 Networking Lunch

    14:00 ENLISTING HEALTHY SPECIMENS TO VERIFY TRIAL RESULTS

    John Connell

    John Connell, Head, Clinical Pharmacodynamics, Medeval Limited

  • What information can healthy volunteer models provide to help accelerate clinical development programmes in anxiety?
  • Can acute volunteer models reflect a chronic disease state?
  • How successful are models at predicting the effects of compounds with novel mechanisms of action?
  • 14:40 VNS THERAPY FOR MOOD DISORDERS

    Renata  Van Woensel

    Renata Van Woensel, Medical Science Liaison, Cyberonics Europe SA

  • Examining the extent and prevalence of the problem
  • Comorbidities
  • Vagus Nerve Stimulation (VNS) therapy: mechanism of action in depression
  • Main clinical trials of VNS in depression
  • 15:20 THE POTENTIAL FOR COMBINATION THERAPIES IN THE TREATMENT OF AFFECTIVE DISORDERS

    Hugh Marston

    Hugh Marston, Head Neurobiology Section, Department of Pharmacology, Organon Labs Ltd.

  • Determining the extent and nature of the problem
  • Do monotherapies offer the potential for effective treatment?
  • What substrates are available adjunctive therapies to address?
  • The current horizon for novel neurotherapeutics
  • Will treatment of residual symptoms cut the risk of relapse?
  • 16:00 Chairman’s Closing Remarks Followed by Afternoon Tea

    +

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.